Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Unlike general immunotherapy reviews, the main contribution of this mini-review is strictly focused on innovative nanomedicine delivery platformsspecifically biomimetic, stimuli-responsive, and bone-targeted systems
Although cardiovascular risk has not been elevated in short-term trials, comprehensive long-term data are still pending
All authors reviewed and approved the final manuscript
over 50% of patients achieved 20 to 25% weight reduction thresholds at 176 weeks Semaglutide 2.4 mg: Up to 13.9% weight loss at 68 weeks Liraglutide 3.0 mg: Approximately 5.8% weight loss at 26 weeks Retatrutide (investigational triple agonist): Up to 22.1% weight loss at 48 weeks A meta-analysis of 47 randomized controlled trials confirmed a mean weight reduction of 4.57 kg, BMI reduction of 2.07 kg/m2, and waist circumference reduction of 4.55 cm versus placebo across all GLP-1 receptor agonists
